Literature DB >> 22354081

Long-term administration of Silymarin augments proinflammatory mediators in the hippocampus of rats: evidence for antioxidant and pro-oxidant effects.

H Malekinejad1, F Rahmani, S Valivande-Azar, M Taheri-Broujerdi, B Bazargani-Gilani.   

Abstract

Silymarin (SMN) is used as an antioxidant complex to attenuate the pro-oxidant effects of toxic agents. This study was designed to investigate the impact of a long-term administration of SMN on proinflammatory mediators, oxidative stress biomarkers and on the levels of interleukin-1β (IL-1β) transcript in the hippocampus. A total of 40 adult male Wistar rats were assigned into control and test groups. Animals in the test group were subdivided into four subgroups according to the following treatment profile: carbon tetrachloride (CCl(4), 0.5 ml/kg), SMN 25, SMN 50 and SMN 100 (mg/kg). The animals received the compounds by gastric gavage. Following the 8-week treatment period, animals in the CCl(4) group showed body weight loss, while the test groups except SMN 100 revealed a significant (p < 0.05) positive body weight gain. The levels of nitric oxide (NO) and malondialdehyde (MDA) as pro-oxidant and lipid peroxidation index, respectively, increased in CCl(4)- and SMN 100-treated groups, while SMN at lower dose levels did not alter the NO and MDA content. The concentration of total thiol molecules increased in the SMN 50 group and showed a remarkable decrease in CCl(4) and SMN 100 groups. Animals treated with CCl(4) or SMN 100 showed an upregulation of IL-1β, while animals in SMN 25 and SMN 50 groups showed a slight downregulation of expression of IL-1β at the messenger RNA level. These findings suggest that SMN at higher dosage level might exert pro-oxidant effect as an increase in the level of MDA and proinflammatory mediators such as NO, and upregulation of IL-1β in the hippocampus were shown.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22354081     DOI: 10.1177/0960327112436405

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  6 in total

1.  Evaluation of HepaRG cells for the assessment of indirect drug-induced hepatotoxicity using INH as a model substance.

Authors:  Anika Mann; Thomas Pelz; Knut Rennert; Alexander Mosig; Michael Decker; Amelie Lupp
Journal:  Hum Cell       Date:  2017-05-19       Impact factor: 4.174

2.  Silymarin mitigates lung impairments in a rat model of acute respiratory distress syndrome.

Authors:  Zhongming Zhu; Gengyun Sun
Journal:  Inflammopharmacology       Date:  2017-11-02       Impact factor: 4.473

3.  Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats.

Authors:  Hassan Malekinejad; Shirin Rokhsartalab-Azar; Sepideh Hassani-Dizaj; Shahin Alizadeh-Fanalou; Aysa Rezabakhsh; Amir Amniattalab
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-12-18       Impact factor: 2.441

4.  Mycophenolate mofetil alters the antioxidant status in duodenum of rats: Implication for silymarin usage in mycophenolate mofetil-induced gastrointestinal disorders.

Authors:  Sanaz Sheikhzadeh; Hassan Malekinejad; Rahim Hobbenaghi
Journal:  Vet Res Forum       Date:  2013       Impact factor: 1.054

5.  Silymarin attenuates mycophenolate mofetil-induced duodenal disorders in rats.

Authors:  Hassan Malekinejad; Sanaz Sheikhzadeh; Rahim Hobbenaghi
Journal:  Avicenna J Phytomed       Date:  2014-05

6.  An Evaluation of the In Vitro Roles and Mechanisms of Silibinin in Reducing Pyrazinamide- and Isoniazid-Induced Hepatocellular Damage.

Authors:  Zhang-He Goh; Jie Kai Tee; Han Kiat Ho
Journal:  Int J Mol Sci       Date:  2020-05-25       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.